Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Times Interest Earned for 3 consecutive years, with -$928119.2 as the latest value for Q1 2022.

  • Quarterly Times Interest Earned fell 416962.55% to -$928119.2 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was -$3.6 million through Dec 2022, down 489095.22% year-over-year, with the annual reading at -$741.16 for FY2021, 673.17% down from the prior year.
  • Times Interest Earned for Q1 2022 was -$928119.2 at Inhibikase Therapeutics, down from -$31908.0 in the prior quarter.
  • The five-year high for Times Interest Earned was -$52.08 in Q2 2020, with the low at -$928119.2 in Q1 2022.
  • Average Times Interest Earned over 3 years is -$109939.3, with a median of -$222.54 recorded in 2021.
  • The sharpest move saw Times Interest Earned crashed 205.98% in 2021, then tumbled 416962.55% in 2022.
  • Over 3 years, Times Interest Earned stood at -$168.21 in 2020, then plummeted by 18869.2% to -$31908.0 in 2021, then tumbled by 2808.74% to -$928119.2 in 2022.
  • According to Business Quant data, Times Interest Earned over the past three periods came in at -$928119.2, -$31908.0, and -$28478.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.